Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07255729 · ClinicalTrials.gov registry record
An Exosomal microRNA Signature for Preoperative Staging in Colon Cancer
A clinical trial of Colon Cancer, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- 400
- Enrollment target
- 1
- Study location
NCT07255729 is a study of Colon Cancer that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 400 participants, below the 4,452-participant average among 97 other Colon Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07255729, a study of Colon Cancer, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
Recent studies have highlighted the potential benefits of neoadjuvant chemotherapy (NAC) in colon cancer; however, its indication is generally limited to cases corresponding to pathological stage IIB or higher. Accurately identifying such high-risk cases before surgery remains challenging using conventional clinical diagnostics alone. Therefore, we hypothesized that integrating molecular biomarkers with preoperative clinical assessment could provide a more precise and sensitive evaluation of tumor aggressiveness. In this context, we focused on exosomal microRNAs, which are actively secreted from tumor cells and remain stable in circulation, and aimed to develop a machine learning-based biomarker panel. To achieve this, we initiated a multicenter study utilizing preoperative plasma samples to establish a reliable biomarker model for risk stratification and treatment decision-making in colon cancer.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Diagnostic Test: EXPOSE assay（Small RNA-seq of exosomal miRNAs）
- DIAGNOSTIC_TEST Diagnostic Test: EXPOSE RT-qPCR panel
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2025-01-15 |
| Est. Completion | 2026-06-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07255729
The ClinicalTrials.gov registry entry for NCT07255729 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,452-participant average among 97 other Colon Cancer trials with a reported enrollment target (91% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colon Cancer appearing as the primary indexed condition, and to 2 interventions - of which Diagnostic Test: EXPOSE assay（Small RNA-seq of exosomal miRNAs） is the first listed.
NCT07255729 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07255729 about?
NCT07255729 is a clinical study titled "An Exosomal microRNA Signature for Preoperative Staging in Colon Cancer". Recent studies have highlighted the potential benefits of neoadjuvant chemotherapy (NAC) in colon cancer; however, its indication is generally limited to cases corresponding to pathological stage IIB or higher. Accurately identifying such high-risk cases before surgery remains challenging using conv...
What is the current status of trial NCT07255729?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2025-01-15. Estimated completion is 2026-06-18.
What conditions does trial NCT07255729 study?
This clinical trial studies the following conditions: Colon Cancer.
What interventions are being tested in trial NCT07255729?
The interventions under investigation include: Diagnostic Test: EXPOSE assay（Small RNA-seq of exosomal miRNAs） (DIAGNOSTIC_TEST), Diagnostic Test: EXPOSE RT-qPCR panel (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07255729?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07255729 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colon Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
-
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.